Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Histopathology. 2019 Aug;75(2):213-224. doi: 10.1111/his.13879. Epub 2019 Jul 10.
Secretory carcinoma of the breast (SCB) is a rare histological type of breast carcinoma with a generally indolent clinical behaviour. We aim to elucidate the clinical, pathological and molecular findings of SCB cases and identify characteristics associated with aggressive clinical courses.
Fourteen patients with SCB were identified, including 12 women and two men, with a median age of 56 years (range = 8-81 years). Clinical data, histological diagnosis, molecular findings and follow-up were reviewed. Eight patients presented with palpable masses and four patients with radiographic abnormalities. All cases were unilateral. Surgical procedures included excisional biopsies and ipsilateral mastectomies. In 10 cases, oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) results were obtained, with six cases positive for ER and three positive for PR. All cases lacked HER2 overexpression. Sentinel lymph node biopsy was performed in 10 cases, and two patients had axillary lymph node metastasis. Follow-up ranged from 21 to 212 months (median = 70 months). Two patients developed distant metastasis of SCB. Molecular analysis of these aggressive tumours revealed amplification of the 16p13.3 locus, a TERT promotor mutation and loss of 9p21.3 locus. Review of the literature for SCB cases with distant metastasis was performed.
Although SCBs are generally associated with a favourable prognosis, our study and review demonstrate that a subset of SCBs may develop distant metastases. Further studies are warranted to identify markers predictive of more aggressive clinical behaviour in this rare breast cancer subtype.
乳腺分泌性癌(SCB)是一种罕见的乳腺癌组织学类型,其临床行为通常较为惰性。我们旨在阐明 SCB 病例的临床、病理和分子特征,并确定与侵袭性临床病程相关的特征。
共确定了 14 例 SCB 患者,包括 12 名女性和 2 名男性,中位年龄为 56 岁(范围= 8-81 岁)。回顾了临床数据、组织学诊断、分子发现和随访情况。8 例患者出现可触及的肿块,4 例患者出现影像学异常。所有病例均为单侧。手术包括切除活检和同侧乳房切除术。在 10 例病例中获得了雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体 2(HER2)的结果,其中 6 例 ER 阳性,3 例 PR 阳性。所有病例均无 HER2 过表达。10 例患者进行了前哨淋巴结活检,其中 2 例患者腋窝淋巴结转移。随访时间从 21 到 212 个月(中位数= 70 个月)不等。2 例患者发生 SCB 远处转移。对这些侵袭性肿瘤的分子分析显示 16p13.3 基因座扩增、TERT 启动子突变和 9p21.3 基因座缺失。对文献中发生远处转移的 SCB 病例进行了回顾。
尽管 SCB 通常与良好的预后相关,但我们的研究和综述表明,一部分 SCB 可能发生远处转移。需要进一步研究以确定这种罕见乳腺癌亚型中更具侵袭性临床行为的预测标志物。